background-image

Metabolism

Semaglutide and Lisinopril Exerts Therapeutic Benefits in a Genetically Engineered Diabetic Nephropathy Mouse Model

2025-06-23

1750815032210029886_undefined.jpeg

Download download

Diabetic nephropathy (DN) is a major driver of chronic kidney disease, yet preclinical models often fail to replicate human disease severity. GemPharmatech addresses this by developing an improved translational DN mouse model that mimics progressive human kidney damage—enabling better evaluation of future therapies.


Submit Inquiry

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

Additional Info

Submitarrowarrow

Contact Us

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Schedule a Meeting

Let us know which event you're attending and we'd be happy to connect with you.

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Area of interest*

Select Area of Interest

Research Focus

How did you hear about us*

Select a source

Leave us a message

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Download

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Watch On-Demand Webinar

First Name*

Last Name*

Organization*

Email*

Country/Region

Select Country/Region

State/Province*

City

Research Focus

Submitarrowarrow

Newsletter Signup

First Name*

Last Name*

Organization*

Email*

Country/Region*

Select Country/Region

Area of interest*

Select Area of Interest

Research Focus

Submitarrowarrow